| Pharmaceutical Information |
| Drug Name |
Umeclidinium bromide |
| Drug ID |
BADD_D02315 |
| Description |
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). It is available as a once-daily inhalation monotherapy or as a fixed-dose combination product with the long-acting beta2-agonist vilanterol. COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%. By blocking the M3 muscarinic receptor which is highly expressed in airway smooth muscle of the lungs, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. Its use has been shown to provide clinically significant, sustained improvements in lung function. |
| Indications and Usage |
Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). |
| Marketing Status |
Not Available |
| ATC Code |
R03BB07 |
| DrugBank ID |
DB09076
|
| KEGG ID |
D10181
|
| MeSH ID |
C573971
|
| PubChem ID |
11519069
|
| TTD Drug ID |
D09ZOQ
|
| NDC Product Code |
58175-0626; 64918-1918; 47848-055; 52482-012; 64567-0030 |
| Synonyms |
GSK573719 | umeclidinium |
|
| Chemical Information |
| Molecular Formula |
C29H34BrNO2 |
| CAS Registry Number |
869113-09-7 |
| SMILES |
C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-] |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
